161 related articles for article (PubMed ID: 17925592)
1. Effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs on urinary sodium excretion, blood pressure, and other renal function indicators in elderly subjects consuming a controlled sodium diet.
Schwartz JI; Thach C; Lasseter KC; Miller J; Hreniuk D; Hilliard DA; Snyder KM; Gertz BJ; Gottesdiener KM
J Clin Pharmacol; 2007 Dec; 47(12):1521-31. PubMed ID: 17925592
[TBL] [Abstract][Full Text] [Related]
2. Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet.
Schwartz JI; Vandormael K; Malice MP; Kalyani RN; Lasseter KC; Holmes GB; Gertz BJ; Gottesdiener KM; Laurenzi M; Redfern KJ; Brune K
Clin Pharmacol Ther; 2002 Jul; 72(1):50-61. PubMed ID: 12152004
[TBL] [Abstract][Full Text] [Related]
3. Effects of specific COX-2-inhibition on renin release and renal and systemic prostanoid synthesis in healthy volunteers.
Stichtenoth DO; Marhauer V; Tsikas D; Gutzki FM; Frölich JC
Kidney Int; 2005 Nov; 68(5):2197-207. PubMed ID: 16221219
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen.
De Vecchis R; Baldi C; Di Biase G; Ariano C; Cioppa C; Giasi A; Valente L; Cantatrione S
Minerva Cardioangiol; 2014 Dec; 62(6):437-48. PubMed ID: 25029569
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies.
Bingham CO; Sebba AI; Rubin BR; Ruoff GE; Kremer J; Bird S; Smugar SS; Fitzgerald BJ; O'Brien K; Tershakovec AM
Rheumatology (Oxford); 2007 Mar; 46(3):496-507. PubMed ID: 16936327
[TBL] [Abstract][Full Text] [Related]
6. Effects of selective COX-2 inhibition on prostanoids and platelet physiology in young healthy volunteers.
Graff J; Skarke C; Klinkhardt U; Watzer B; Harder S; Seyberth H; Geisslinger G; Nüsing RM
J Thromb Haemost; 2007 Dec; 5(12):2376-85. PubMed ID: 17916229
[TBL] [Abstract][Full Text] [Related]
7. Celecoxib in the treatment of primary dysmenorrhea: results from two randomized, double-blind, active- and placebo-controlled, crossover studies.
Daniels S; Robbins J; West CR; Nemeth MA
Clin Ther; 2009 Jun; 31(6):1192-208. PubMed ID: 19695387
[TBL] [Abstract][Full Text] [Related]
8. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
Sowers JR; White WB; Pitt B; Whelton A; Simon LS; Winer N; Kivitz A; van Ingen H; Brabant T; Fort JG;
Arch Intern Med; 2005 Jan; 165(2):161-8. PubMed ID: 15668361
[TBL] [Abstract][Full Text] [Related]
9. Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 versus COX-1 in healthy subjects.
Schwartz JI; Dallob AL; Larson PJ; Laterza OF; Miller J; Royalty J; Snyder KM; Chappell DL; Hilliard DA; Flynn ME; Cavanaugh PF; Wagner JA
J Clin Pharmacol; 2008 Jun; 48(6):745-54. PubMed ID: 18434566
[TBL] [Abstract][Full Text] [Related]
10. Comparative impact on prostanoid biosynthesis of celecoxib and the novel nonsteroidal anti-inflammatory drug CG100649.
Skarke C; Alamuddin N; Lawson JA; Cen L; Propert KJ; Fitzgerald GA
Clin Pharmacol Ther; 2012 Jun; 91(6):986-93. PubMed ID: 22278334
[TBL] [Abstract][Full Text] [Related]
11. Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials.
Curtis SP; Ng J; Yu Q; Shingo S; Bergman G; McCormick CL; Reicin AS
Clin Ther; 2004 Jan; 26(1):70-83. PubMed ID: 14996519
[TBL] [Abstract][Full Text] [Related]
12. [Effect of nonsteroidal anti-inflammatory drugs on the indicators of cardiovascular risk in patients with acute nonspecific back pain].
Zolotovskaya IA; Davydkin IL
Ter Arkh; 2015; 87(12):18-25. PubMed ID: 26978413
[TBL] [Abstract][Full Text] [Related]
13. Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial.
Goldstein JL; Cryer B; Amer F; Hunt B
Clin Gastroenterol Hepatol; 2007 Oct; 5(10):1167-74. PubMed ID: 17916545
[TBL] [Abstract][Full Text] [Related]
14. Urinary prostaglandin excretion in pregnancy: the effect of dietary sodium restriction.
Delemarre FM; Thomas CM; van den Berg RJ; Jongsma HW; Steegers EA
Prostaglandins Leukot Essent Fatty Acids; 2000 Oct; 63(4):209-15. PubMed ID: 11049696
[TBL] [Abstract][Full Text] [Related]
15. Extent of renal effect of cyclo-oxygenase-2-selective inhibitors is pharmacokinetic dependent.
Harirforoosh S; Aghazadeh-Habashi A; Jamali F
Clin Exp Pharmacol Physiol; 2006 Oct; 33(10):917-24. PubMed ID: 17002668
[TBL] [Abstract][Full Text] [Related]
16. Safety of etoricoxib, a new cyclooxygenase 2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedema.
Sánchez-Borges M; Caballero-Fonseca F; Capriles-Hulett A
Ann Allergy Asthma Immunol; 2005 Aug; 95(2):154-8. PubMed ID: 16136765
[TBL] [Abstract][Full Text] [Related]
17. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids.
Catella-Lawson F; McAdam B; Morrison BW; Kapoor S; Kujubu D; Antes L; Lasseter KC; Quan H; Gertz BJ; FitzGerald GA
J Pharmacol Exp Ther; 1999 May; 289(2):735-41. PubMed ID: 10215647
[TBL] [Abstract][Full Text] [Related]
18. Relative efficacy and tolerability of etoricoxib, celecoxib, and naproxen in the treatment of osteoarthritis : A Bayesian network meta-analysis of randomized controlled trials based on patient withdrawal.
Song GG; Seo YH; Kim JH; Choi SJ; Ji JD; Lee YH
Z Rheumatol; 2016 Jun; 75(5):508-16. PubMed ID: 26768273
[TBL] [Abstract][Full Text] [Related]
19. Effects of sulindac and naproxen on prostaglandin excretion in patients with impaired renal function and rheumatoid arthritis.
Eriksson LO; Sturfelt G; Thysell H; Wollheim FA
Am J Med; 1990 Sep; 89(3):313-21. PubMed ID: 2203262
[TBL] [Abstract][Full Text] [Related]
20. Renal effects of the cyclooxygenase-inhibiting nitric oxide donator AZD3582 compared with rofecoxib and naproxen during normal and low sodium intake.
Huledal G; Jonzon B; Malmenäs M; Hedman A; Andersson LI; Odlind B; Brater DC
Clin Pharmacol Ther; 2005 May; 77(5):437-50. PubMed ID: 15900289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
